KEGG   DRUG: Tocilizumab
Entry
D02596                      Drug                                   
Name
Tocilizumab (USAN/INN);
Tocilizumab (genetical recombination) (JAN);
Actemra (TN)
Product
TOCILIZUMAB (Genentech)
Formula
C6428H9976N1720O2018S42
Exact mass
144895.9145
Mol weight
144985.0322
Class
Immunological agent
 DG02019  Interleukin inhibitor
Anti-inflammatory
 DG01985  Disease modifying anti-rheumatic drug (DMARD)
Remark
Therapeutic category: 6399
ATC code: L04AC07
Product: D02596<JP/US>
Efficacy
Anti-inflammatory, Antirheumatic, Immunosuppressant, Anti-IL-6 receptor antibody
  Disease
Rheumatoid arthritis [DS:H00630]
Giant Cell Arteritis [DS:H01698]
Systemic sclerosis-associated interstitial lung disease [DS:H01492]
Polyarticular juvenile idiopathic arthritis [DS:H01672]
Systemic juvenile idiopathic arthritis [DS:H01672]
  Type
Monoclonal antibody
Comment
Treatment of cytokine release syndrome
Target
IL6R (CD126) [HSA:3570] [KO:K05055]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04630  JAK-STAT signaling pathway
hsa04640  Hematopoietic cell lineage
Interaction
Structure map
map07050  Antirheumatics - DMARDs and biological agents
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AC Interleukin inhibitors
     L04AC07 Tocilizumab
      D02596  Tocilizumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Immunological Agents, Other
   Interleukin Blockers
    Tocilizumab
     D02596  Tocilizumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   639  Miscellaneous
    6399  Others
     D02596  Tocilizumab (USAN/INN); Tocilizumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Immunological agent
  DG02019  Interleukin inhibitor
   D02596  Tocilizumab
 Anti-inflammatory
  DG01985  Disease modifying anti-rheumatic drug (DMARD)
   D02596  Tocilizumab
Drug classes [BR:br08332]
 Immunological agent
  DG02019  Interleukin inhibitor
   D02596  Tocilizumab
 Antirheumatic agent
  DG01985  Disease modifying anti-rheumatic drug (DMARD)
   D02596  Tocilizumab
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Interleukin receptors
    IL6R (CD126)
     D02596  Tocilizumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D02596
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D02596
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D02596
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D02596
Other DBs
CAS: 375823-41-9
PubChem: 17396767
NIKKAJI: J2.104.935B
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system